Latest Blogs

Mar 21, 2023
Dr. Michael LaPelusa shares his recent start-to-finish experience going through the Fellowship Match, with tips for preparing your application, interviewing, and telling your unique professional story.
Mar 16, 2023
Clear expectations are key for effective teamwork. Tammy Triglianos, Dr. Ethan Basch, and Dr. Matthew Milowsky share a guidance document to facilitate excellent collaboration in advanced practice provider/physician teams.
Mar 14, 2023
Four geriatric oncology experts answer five questions about the field, including what oncology trainees need to know, how to pursue consolidated training, and why geriatric oncology is a meaningful and rewarding career.
Mar 14, 2023
Dr. Khalid El Bairi was invited to participate in the International Summit of Health Professionals in Pakistan, a country he only knew from the news and nature documentaries. The visit challenged his perceptions and allowed him to make valuable connections.
Subscribe to this column

Gilberto Lopes, MD, FASCO, MBA

Gilberto de Lima Lopes Jr., MD, MBA, FAMS, is associate director for global oncology and interim chief for the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center and professor of clinical medicine at the University of Miami in Florida. He returned to the United States after 10 years in Asia and Latin America and has dedicated much of his time to the issues of cancer control and access to medications in low- and middle-income countries. Dr. Lopes is the editor-in-chief for JCO Global Oncology, among other volunteer roles at ASCO. Follow him on Twitter @GlopesMd.

Disclosure.

Jul 26, 2017
My coauthors and I identify deficiencies in prevention and screening efforts that could be acted upon to further reduce cervical cancer incidence and mortality in Latin America.
Mar 20, 2017
When the basics of cancer control are not in place, should we discuss targeted agents and immunotherapy in resource-constrained settings?
Oct 31, 2016
Hope springs eternal in the Brazilian economy and health care system, with cautious optimism for gains in oncology care.
Oct 04, 2016
Inequalities, especially in health care, breed discontent. We need better ways to continue incentivizing the development of new drugs while optimizing access. Biosimilars help, but they won't solve the whole problem.
Aug 01, 2016
The region has seen structural reforms in health care systems, better training of cancer professionals, new initiatives for populations at high risk, expansion of cancer registries and cancer plans, and implementation of policies to improve prevention, early diagnosis, and treatment.
Jul 11, 2016
Follow-on biologics are here to stay, and represent enormous potential for patients with cancer being treated in low- and middle-income countries.

Pages